1. Immunohistochemistry of pulmonary biomarkers : a perspective from members of the pulmonary pathology societyErik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Luiza Capelozzi, Wendy Cooper, Izidor Kern, 2018, izvirni znanstveni članek Povzetek: The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK, (ROS1, EGFR in Europe), and programmed death ligand-1 (PD-L1) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes. Ključne besede: pulmonary biomarkers, immunohistochemistry, pathology Objavljeno v DiRROS: 17.12.2020; Ogledov: 1341; Prenosov: 494
Povezava na datoteko |